Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM).

2019 ◽  
Vol 19 (10) ◽  
pp. e259
Author(s):  
Julie Stakiw ◽  
Vishal Kukreti ◽  
Richard LeBlanc ◽  
Michael Sebag ◽  
Annette Hay ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Infusion Rate ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Initial Results

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase

Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma

2017 ◽  
Vol 59 (5) ◽  
pp. 1271-1273 ◽  
Author(s):  
Massimo Offidani ◽  
Laura Corvatta ◽  
Anna Marina Liberati ◽  
Stefano Pulini ◽  
Stelvio Ballanti ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study

Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2717-2717 ◽  
Author(s):  
Sundar Jagannath ◽  
Bart Barlogie ◽  
James R. Berenson ◽  
David Siegel ◽  
D. Irwin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Initial Report ◽  
Refractory Multiple Myeloma ◽  
Kaplan Meier ◽  
Phase 2 Study ◽  
The Difference ◽  
Dose Levels ◽  
To Receive

Abstract Background: The initial report of the CREST phase 2 study (Br J Haematol2004;127:165–72) demonstrated the substantial activity of bortezomib (VELCADE®, Vc) at two different dose levels in patients with relapsed or refractory multiple myeloma (MM). Here, we provide an updated analysis of overall survival (OS) after prolonged follow-up (median >5 years). Methods: 54 patients were enrolled to receive Vc 1.0 mg/m2 (n=28) or 1.3 mg/m2 (n=26) on days 1, 4, 8, and 11 of a 21-day cycle, for up to 8 cycles. Dexamethasone (dex) 20 mg on the day of and day after each Vc dose was added for 16 (57%) patients in the 1.0 mg/m2 group and 12 (46%) patients in the 1.3 mg/m2 group, upon suboptimal response to Vc alone. A total of 17 (31%) patients continued to receive Vc ± dex in an extension study, 12 (43%) from the 1.0 mg/m2 and 5 (19%) from the 1.3 mg/m2 groups. Patients received a median of 3 (range, 1–7) prior regimens. Median time from diagnosis to first Vc dose was 2 years. In the 1.0 and 1.3 mg/m2 groups, respectively, mean age was 64 vs 60 years, 50% vs 35% of patients were male, 54% vs 65% had IgG MM, 58% vs 48% had β2-microglobulin ≥4 mg/L, and 29% vs 48% had abnormal cytogenetics. Response rate (CR+PR, EBMT criteria) to Vc alone was 30% vs 38%, and to Vc ± dex was 37% vs 50% in the 1.0 and 1.3 mg/m2 groups. OS from first dose of Vc in each dose group was analyzed using the Kaplan-Meier method. Results: Median OS in the 1.0 and 1.3 mg/m2 groups was 26.8 months and 60.0 months, after median follow-up of 61 and 65 months, respectively (Figure). In the 1.0 mg/m2 group, 21 (75%) patients have died; the 1- and 2-year OS rates were 82% and 54%, respectively. In the 1.3 mg/m2 group, only 14/26 (54%) patients have died; 1- and 2-year OS rates were 81% and 69%, respectively. Conclusions: Vc ± dex was active in relapsed or refractory MM at both the 1.0 mg/m2 and 1.3 mg/m2 dose levels and was associated with notable OS, particularly in patients treated with the approved Vc dose of 1.3 mg/m2. The difference in OS between dose groups suggests that the higher dose of Vc is more active. Figure. Kaplan-Meier analyses of OS in patients who received Vc 1.0 mg/m2 (n=28) or 1.3 mg/m2 (n=26). Figure Figure

A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS8066-TPS8066 ◽  
Author(s):  
Jesus San Miguel ◽  
Marc S. Raab ◽  
Hartmut Goldschmidt ◽  
Sagar Lonial ◽  
Paul G. Richardson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Randomized Phase 2
Sign in / Sign up

Export Citation Format

Share Document